Search Results
Your search for Matthew Stenger,Matthew Stenger matches 7831 pages
Showing 2301 - 2350Adding First-Line Nivolumab to Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinomas
As reported in The Lancet by Yelena Y. Janjigian, MD, of the Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CheckMate 649 trial has shown that the addition of first-line nivolumab to chemotherapy resulted in improved overall and...
Consolidation Treatment With VRD Followed by Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma
In a phase III European Myeloma Network trial (EMN02/HOVON95) reported in the Journal of Clinical Oncology, Sonneveld et al found that consolidation with bortezomib, lenalidomide, and dexamethasone (VRD) vs no consolidation followed by maintenance lenalidomide was associated with significantly...
Does Adjuvant Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer Lead to Increased Rates of Late Toxicity?
In the Indian single-center phase III PARCER trial reported in the Journal of Clinical Oncology, Supriya Chopra, MD, DNB, and colleagues found that adjuvant image-guided intensity-modulated radiotherapy (IG-IMRT) was associated with less late grade ≥ 2 gastrointestinal toxicity vs three-dimensional ...
First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia
In a phase II study reported in The Lancet Oncology, Matthew S. Davids, MD, and colleagues found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced measurable residual disease (MRD)-negative complete remission in a substantial proportion of patients ...
Long-Term Outcomes in JULIET Trial of Tisagenlecleucel for Relapsed or Refractory Aggressive B-Cell Lymphomas
As reported by Stephen J. Schuster, MD, and colleagues in The Lancet Oncology, long-term outcomes of the pivotal phase II JULIET trial showed overall and complete response rates of 53% and 39% in adult patients with relapsed or refractory aggressive B-cell lymphomas treated with the T-cell...
Single-Fraction vs Multifraction SABR for Pulmonary Oligometastases: Is There a Difference in Safety or Efficacy?
In the phase II SAFRON II study reported in JAMA Oncology, Shankar Siva, PhD, MBBS, FRANZCR, and colleagues found no significant differences in safety or efficacy between single-fraction vs multifraction stereotactic ablative body radiotherapy (SABR) for the treatment of pulmonary oligometastases. ...
Association of Pathologic Residual Cancer Burden and Event-Free Survival After Neoadjuvant Treatment for High-Risk Breast Cancer
In an analysis from the I-SPY2 trial reported in JAMA Oncology, W. Fraser Symmans, MD, and colleagues found that increasing residual cancer burden after neoadjuvant treatment for high-risk breast cancer was associated with poorer event-free survival. Study Details In I-SPY2, investigational agents...
DESTINY-Lung01: Fam-trastuzumab Deruxtecan-nxki in Previously Treated HER2-Mutant NSCLC
In the phase II DESTINY-Lung01 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract LBA45) and concurrently reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable...
COSMIC-021: Cabozantinib Plus Atezolizumab for Advanced Renal Cell Carcinoma
In the phase Ib COSMIC-021 trial reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the combination of cabozantinib and atezolizumab produced durable responses in patients with advanced renal cell carcinoma (RCC). Study Details One hundred and two...
Addition of Ramucirumab to Gemcitabine in Second-Line Treatment of Malignant Pleural Mesothelioma
In the Italian phase II RAMES trial reported in The Lancet Oncology, Pinto et al found that the addition of ramucirumab to gemcitabine improved overall survival in the second-line treatment of malignant pleural mesothelioma. As noted by the investigators, “There is a preclinical rationale for...
COVID-19 Lockdown May Be Associated With Higher Tumor Burden in Newly Diagnosed Patients With Metastatic Colorectal Cancer
In a French study reported in JAMA Network Open, Thierry et al found that tumor burden (assessed as plasma circulating tumor DNA [ctDNA]) was significantly higher among patients with newly diagnosed metastatic colorectal cancer screened for a clinical trial after vs before the first COVID-19...
Mortality Trends After Allogeneic Blood or Marrow Transplantation
In an analysis from a Blood or Marrow Transplant Survivor Study cohort reported in JAMA Oncology, Smita Bhatia, MD, MPH, and colleagues found that late mortality among patients undergoing allogeneic blood or marrow transplantation for hematologic malignancies has declined over the past 40 years,...
Estimated Impact of the COVID-19 Pandemic on Cancer Diagnosis and Survival in Chile Over the Next Decade
In a simulation-based study reported in The Lancet Oncology, Ward et al estimated that delay in diagnosis due to the COVID-19 pandemic in Chile will lead to an early surge of newly diagnosed cancers at later stages, resulting in excess mortality over the next 10 years. As stated by the...
Bispecific Antibody Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
In a phase I/II study reported in The Lancet, Hutchings et al found that the novel bispecific antibody epcoritamab produced high response rates in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Epcoritamab works by targeting CD3 and CD20 and inducing T-cell–mediated cytotoxic...
Association of Skeletal Muscle Area and Adiposity Measures With Inflammation and Outcomes in Nonmetastatic Colon Cancer
In a study reported in JAMA Network Open, Fleming et al found that low skeletal muscle area and high visceral-to-total fat ratio were associated with increased expression of proinflammatory cytokines and VEGF as well as worse 5-year outcomes in patients with nonmetastatic colon cancer. Study...
Nivolumab vs Gemcitabine or Pegylated Liposomal Doxorubicin: What Regimen Improves Survival in Platinum-Resistant Ovarian Cancer?
In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer. Study Details In the...
Inclusion of Women in Oncology Clinical Trials From 2000 to 2020
In a study reported in a research letter in JAMA Oncology, Jenei et al found that women with cancer have been underrepresented in global oncology drug trials over the past 20 years, with underrepresentation persisting through the present in multiple cancer types. Study Details The study involved ...
Rates of Adverse Reactions to the Moderna mRNA-1273 COVID-19 Vaccine in Patients With Cancer and Recent Radiotherapy
In an Italian single-center study reported in a letter in The Lancet Oncology, Scoccianti et al found that patients who underwent radiotherapy for cancer within the 6 months prior to receipt of the Moderna mRNA-1273 COVID-19 vaccine did not experience a difference in adverse reactions to the...
AUTO1: CAR T-Cell Product for Adult Patients With Relapsed or Refractory B-Cell ALL
In a phase I trial (ALLCAR19) reported in the Journal of Clinical Oncology, Roddie et al found that the fast off-rate autologous CD19 chimeric antigen receptor (CAR) T-cell therapy CAT19-41BB-Z—also known as AUTO1—was well tolerated and produced high remission rates in adults with relapsed or...
Cancer-Specific Urgent Care Center: Effect on Emergency Department Use and Hospitalization Rate
In a single-institution study reported in JCO Oncology Practice, Gould Rothberg et al found that establishment of a dedicated cancer urgent care center within a large tertiary academic center resulted in a significant but modest decrease in emergency department use—but no significant reduction in...
Effect of Mindfulness Meditation and Survivorship Education on Depressive Symptoms in Younger Breast Cancer Survivors
In a phase III trial (Pathways to Wellness) reported in the Journal of Clinical Oncology, Julienne E. Bower, PhD, and colleagues found that both mindfulness meditation and survivorship education interventions significantly reduced depressive symptoms in younger breast cancer survivors. Study...
Technology-Enabled Monitoring of Adverse Reactions to Immune Checkpoint Inhibitors
In an interim analysis of a single-institution study reported in JAMA Network Open, Pavlos Msaouel, MD, PhD, and colleagues found that the use of a mobile device application for patient reporting of adverse reactions to immune checkpoint inhibition was feasible. It permitted identification of...
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral...
High Prevalence of Germline BRCA Mutations in Indian Women With Ovarian Cancer
In a prospective cross-sectional study reported in JCO Global Oncology, Sudeep Gupta, MBBS, MD, DM, of Tata Memorial Centre, and colleagues found that Indian women with ovarian cancer not selected for study based on clinical factors had a high prevalence of germline pathogenic or likely pathogenic...
Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Oliver Sartor, MD, of the School of Medicine, Tulane University, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (LuPSMA) radioligand therapy plus standard care vs...
Daratumumab and Hyaluronidase-fihj With Pomalidomide Plus Dexamethasone in Multiple Myeloma
On July 9, 2021, daratumumab and hyaluronidase-fihj was approved for use in combination with pomalidomide and dexamethasone (Pd) for treatment of adults with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.1 Supporting...
Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...
Amivantamab-vmjw for Previously Treated Advanced NSCLC With EGFR Mutation
On May 21, 2021, amivantamab-vmjw, a bispecific antibody directed against EGFR and MET receptors, was granted accelerated approval for treatment of adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Enfortumab Vedotin-ejfv in Urothelial Cancer
On July 9, 2021, enfortumab vedotin-ejfv, an antibody-drug conjugate targeting nectin-4, was granted regular approval. The agent is indicated for the treatment of adults with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor and platinum chemotherapy or...
Pembrolizumab for High-Risk, Early-Stage Triple-Negative Breast Cancer
On July 26, 2021, pembrolizumab was approved for high-risk, early-stage, triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and continued as adjuvant treatment.1 Pembrolizumab was also granted regular approval in combination with chemotherapy for locally...
Resurgence of COVID-19 Infection in a Large, Vaccinated Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Keehner et al describe a marked resurgence of COVID-19 infections among fully vaccinated members of the University of California San Diego Health (UCSDH) workforce in July 2021. The resurgence appears to be driven by the confluence...
Effect of High-Intensity Interval Training on Biochemical Progression in Patients With Localized Prostate Cancer Under Active Surveillance
In a Canadian single-institution phase II study (ERASE) reported in JAMA Oncology, Kang et al found that increased exercise in the form of high-intensity interval training was associated with increased cardiorespiratory fitness and reductions in prostate-specific antigen (PSA) level, PSA velocity,...
Pharmacy Strategy to Decrease Patient Copayments for High-Cost Cancer Drugs Through Financial Assistance Applications
In an observational retrospective study reported in JCO Oncology Practice, Seymour et al describe a strategy used by Karmanos Specialty Pharmacy (KSP) to successfully decrease patient copayments for high-cost cancer drugs. Study Details The study involved data from the KSP claims data set, accessed ...
HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045
In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...
Rates of Newly Diagnosed Cancer Among U.S. Patients During the First Full Year of the COVID-19 Pandemic
In a study of Quest Diagnostics data reported as a research letter in JAMA Network Open, Kaufman et al found significant decreases in monthly new cancer diagnoses during the first full year of the COVID-19 pandemic compared with the prepandemic period. As stated by the investigators, “We previously ...
Ensartinib Shows Superior Efficacy to Crizotinib in Advanced ALK-Positive NSCLC: eXalt3 Trial
As reported in JAMA Oncology by Leora Horn, MD, MSc, FRCPC, and colleagues, the phase III eXalt3 trial has shown significantly prolonged progression-free survival with ensartinib vs crizotinib in patients with advanced, recurrent, or metastatic anaplastic lymphoma kinase (ALK)-positive non–small...
Teleoncology for Veterans With Cancer During the COVID-19 Pandemic
In a single-center study reported in JCO Oncology Practice, Jiang et al found an overall high level of satisfaction with teleoncology care during the COVID-19 pandemic among veterans with cancer in the United States, although a preference for in-person visits was commonly expressed. Teleoncology...
Phase II Trial Evaluates Oncolytic Coxsackievirus A21 for Unresectable Advanced Melanoma
In a phase II trial reported in the Journal of Clinical Oncology, Robert H.I. Andtbacka, MD, and colleagues found that intratumoral injection of the oncolytic RNA virus Coxsackievirus A21 (V937) was well tolerated and produced responses in some patients with unresectable stage III or stage IV...
Ibrutinib and Cardiovascular Risk in Patients With Chronic Lymphocytic Leukemia
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Abdel-Qadir et al found that ibrutinib treatment for chronic lymphocytic leukemia (CLL) is associated with increased risks of atrial fibrillation, bleeding, and heart failure, but not ischemic stroke or acute...
Neoadjuvant Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab for Muscle-Invasive Bladder Cancer
In a phase II study reported in the Journal of Clinical Oncology, Tracy L. Rose, MD, MPH, and colleagues found that neoadjuvant therapy with pembrolizumab, gemcitabine, and primarily split-dose cisplatin resulted in pathologic downstaging (< pT2N0) in more than half of patients undergoing...
Effect of Concurrent Focal 22q11.22 Deletions and IKZF1 Alterations on Outcomes in Pediatric Patients With B-Cell ALL
In a study reported in JAMA Oncology, Mangum et al found that focal deletions in chromosome 22q11.22 were associated with poor outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL) with IKZF1 alterations. As stated by the investigators, “Alterations in the IKZF1 gene drive...
Addition of Everolimus to Letrozole in Premenopausal Women With Advanced HR-Positive, HER2-Negative Breast Cancer
In the Chinese phase II MIRACLE trial reported in JAMA Oncology, Fan et al found that the addition of everolimus to letrozole significantly improved progression-free survival among premenopausal women with advanced hormone receptor (HR)-positive, HER2-negative breast cancer whose disease had...
Effects of COVID-19 Infection in Children and Adolescents With Cancer: Global Analysis
In a Global Registry of COVID-19 in Childhood Cancer cohort study reported in The Lancet Oncology, Mukkada et al found that approximately one-fifth of children with cancer infected with COVID-19 worldwide had severe illness, with an associated mortality rate exceeding that reported in the general...
Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Bahlis et al found that venetoclax plus daratumumab/dexamethasone (VenDd) and VenDd with bortezomib (VenDVd) produced high rates of durable responses in patients with relapsed or refractory multiple myeloma with t(11;14) translocation ...
Addition of ATR Inhibitor Berzosertib to Cisplatin/Gemcitabine in Metastatic Urothelial Carcinoma
In a phase II trial reported in JAMA Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the addition of the ATR inhibitor berzosertib to cisplatin/gemcitabine provided no benefit in patients with metastatic urothelial carcinoma. The triplet did not prolong progression-free survival, and ...
Inguinofemoral Radiotherapy vs Inguinofemoral Lymphadenectomy for Patients With Vulvar Cancer and Sentinel Node Metastasis
In the phase II GROINSS-V II study reported in the Journal of Clinical Oncology, Oonk et al found that inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in women with early-stage vulvar cancer and sentinel node micrometastasis but was associated with a higher...
Global Breast Cancer Survival: Estimated Impact of Scaling Up Access to Treatment/Imaging Modalities and Quality of Care
In a study reported in The Lancet Oncology, Ward et al estimated the improvements in global overall survival for female breast cancer that could be achieved via increased availability of treatment and imaging modalities, as well as improvements in quality of care. Study Details The study used a...
Addition of Pembrolizumab to Chemotherapy for the First-Line Treatment of Advanced Esophageal Cancer: KEYNOTE-590
As reported in The Lancet by Sun et al, the phase III KEYNOTE-590 trial showed that the addition of first-line pembrolizumab to chemotherapy resulted in improved overall and progression-free survival in patients with advanced esophageal and Siewert type 1 gastroesophageal junction (GEJ) cancers....
First-Line Veliparib Plus Platinum-Based Chemotherapy in Current Smokers With Advanced Squamous Cell NSCLC
In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, and colleagues found that the addition of the poly (ADP-ribose) polymerase inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in current smokers with previously untreated...
